122 related articles for article (PubMed ID: 35402241)
1. Effectiveness and Safety of Niraparib as Neoadjuvant Therapy in Advanced Ovarian Cancer With Homologous Recombination Deficiency (NANT): Study Protocol for a Prospective, Multicenter, Exploratory, Phase 2, Single-Arm Study.
Zhou D; Liu J; Liu R; Li H; Huang Y; Ma D; Hong L; Gao Q
Front Oncol; 2022; 12():852772. PubMed ID: 35402241
[TBL] [Abstract][Full Text] [Related]
2. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.
Belotte J; Felicetti B; Baines AJ; YoussefAgha A; Rojas-Espaillat L; Ortiz AG; Provencher D; Vázquez RM; Cortijo LG; Zeng X
Trials; 2024 May; 25(1):301. PubMed ID: 38702828
[TBL] [Abstract][Full Text] [Related]
3. AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial.
Heitz F; Marth C; Henry S; Reuss A; Cibula D; Gaba Garcia L; Colombo N; Schmalfeld B; de Gregorio N; Wimberger P; Hasenburg A; Sehouli J; Gropp-Meier M; Schouten PC; Hahnen E; Hauke J; Polleis S; Harter P
Int J Gynecol Cancer; 2023 Dec; 33(12):1966-1969. PubMed ID: 37935524
[TBL] [Abstract][Full Text] [Related]
4. Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial.
Barretina-Ginesta MP; Monk BJ; Han S; Pothuri B; Auranen A; Chase DM; Lorusso D; Anderson C; Abadie-Lacourtoisie S; Cloven N; Braicu EI; Amit A; Redondo A; Shah R; Kebede N; Hawkes C; Gupta D; Woodward T; O'Malley DM; González-Martín A
Ther Adv Med Oncol; 2022; 14():17588359221126149. PubMed ID: 36172173
[TBL] [Abstract][Full Text] [Related]
5. Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.
Li N; Zhu J; Yin R; Wang J; Pan L; Kong B; Zheng H; Liu J; Wu X; Wang L; Huang Y; Wang K; Zou D; Zhao H; Wang C; Lu W; Lin A; Lou G; Li G; Qu P; Yang H; Zhang Y; Cai H; Pan Y; Hao M; Liu Z; Cui H; Yang Y; Yao S; Zhen X; Hang W; Hou J; Wang J; Wu L
JAMA Oncol; 2023 Sep; 9(9):1230-1237. PubMed ID: 37440217
[TBL] [Abstract][Full Text] [Related]
6. Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.
González-Martín A; Pothuri B; Vergote I; Graybill W; Lorusso D; McCormick CC; Freyer G; Backes F; Heitz F; Redondo A; Moore RG; Vulsteke C; O'Cearbhaill RE; Malinowska IA; Shtessel L; Compton N; Mirza MR; Monk BJ
Eur J Cancer; 2023 Aug; 189():112908. PubMed ID: 37263896
[TBL] [Abstract][Full Text] [Related]
7. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
Konstantinopoulos PA; Waggoner S; Vidal GA; Mita M; Moroney JW; Holloway R; Van Le L; Sachdev JC; Chapman-Davis E; Colon-Otero G; Penson RT; Matulonis UA; Kim YB; Moore KN; Swisher EM; Färkkilä A; D'Andrea A; Stringer-Reasor E; Wang J; Buerstatte N; Arora S; Graham JR; Bobilev D; Dezube BJ; Munster P
JAMA Oncol; 2019 Aug; 5(8):1141-1149. PubMed ID: 31194228
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China.
Ni J; Cheng X; Zhao Q; Dai Z; Xu X; Guo W; Gu H; Zhou R; Wang Y; Chen X
J Ovarian Res; 2021 May; 14(1):68. PubMed ID: 33993885
[TBL] [Abstract][Full Text] [Related]
9. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.
Hardesty MM; Krivak TC; Wright GS; Hamilton E; Fleming EL; Belotte J; Keeton EK; Wang P; Gupta D; Clements A; Gray HJ; Konecny GE; Moore RG; Richardson DL
Gynecol Oncol; 2022 Aug; 166(2):219-229. PubMed ID: 35690498
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China.
Zhao M; Qiu S; Wu X; Miao P; Jiang Z; Zhu T; Xu X; Zhu Y; Zhang B; Yuan D; Zhang Y; Sun W; He A; Zhao M; Hou W; Zhang Y; Shao Z; Jia M; Li M; Chen J; Xu J; Chen B; Zhou Y; Shen Y
Target Oncol; 2023 Nov; 18(6):869-883. PubMed ID: 37847485
[TBL] [Abstract][Full Text] [Related]
11. Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab
Hettle R; McCrea C; Lee CK; Davidson R
Ther Adv Med Oncol; 2021; 13():17588359211049639. PubMed ID: 34616492
[TBL] [Abstract][Full Text] [Related]
12. NIRVANA-1: maintenance therapy with niraparib versus niraparib-bevacizumab in patients with advanced ovarian cancer.
Sghaier S; Corbaux P; Ray-Coquard I; Lim MC; Hasegawa K; Nieuwenhuysen EV; Gonzalez A; Raspagliesi F; Freyer G
Future Oncol; 2023 Aug; 19(25):1715-1727. PubMed ID: 37650734
[TBL] [Abstract][Full Text] [Related]
13. Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial.
Liu JF; Gaillard S; Wahner Hendrickson AE; Yeku O; Diver E; Gunderson Jackson C; Arend R; Ratner E; Samnotra V; Gupta D; Chung J; Zhang H; Compton N; Baines A; Bacqué E; Liu X; Felicetti B; Konecny GE
JCO Precis Oncol; 2024 May; 8():e2300693. PubMed ID: 38754056
[TBL] [Abstract][Full Text] [Related]
14. Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer.
Goh JCH; Gourley C; Tan DSP; Nogueira-Rodrigues A; Elghazaly H; Edy Pierre M; Giornelli G; Kim BG; Morales-Vasquez F; Tyulyandina A
Gynecol Oncol Rep; 2022 Aug; 42():101028. PubMed ID: 35813356
[TBL] [Abstract][Full Text] [Related]
15. Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion.
Vergote I; Denys H; Altintas S; Kerger J; Baurain JF; Bours V; Henry S; Van de Vijver K; Lambrechts D; Gennigens C
Facts Views Vis Obgyn; 2022 Jun; 14(2):111-120. PubMed ID: 35781107
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Minimally Invasive Surgery Versus Open Laparotomy for Interval Debulking Surgery of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy: A Systematic Review and A Meta-Analysis.
Zeng S; Yu Y; Cui Y; Liu B; Jin X; Li Z; Liu L
Front Oncol; 2022; 12():900256. PubMed ID: 35924170
[TBL] [Abstract][Full Text] [Related]
17. [Évolution des traitements adjuvants des cancers de l'ovaire].
Pautier P
Rev Prat; 2022 Jun; 72(6):633-637. PubMed ID: 35899664
[TBL] [Abstract][Full Text] [Related]
18. Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial.
Capoluongo ED; Pellegrino B; Arenare L; Califano D; Scambia G; Beltrame L; Serra V; Scaglione GL; Spina A; Cecere SC; De Cecio R; Normanno N; Colombo N; Lorusso D; Russo D; Nardelli C; D'Incalci M; Llop-Guevara A; Pisano C; Baldassarre G; Mezzanzanica D; Artioli G; Setaro M; Tasca G; Roma C; Campanini N; Cinieri S; Sergi A; Musolino A; Perrone F; Chiodini P; Marchini S; Pignata S
ESMO Open; 2022 Oct; 7(5):100585. PubMed ID: 36156447
[TBL] [Abstract][Full Text] [Related]
19. PARP inhibitor maintenance treatment for newly diagnosed ovarian cancer patients: a real-world study from China.
Chen J; Zhang M; Li K; Duan Y; Zeng J; Li Q; Wang D; Song L; Li Q; Yin R
Front Oncol; 2024; 14():1336616. PubMed ID: 38371630
[TBL] [Abstract][Full Text] [Related]
20. IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation.
Kato T; Matsubara N; Shiota M; Eto M; Osawa T; Abe T; Shinohara N; Yasumizu Y; Tanaka N; Oya M; Nishimoto K; Hayashi T; Nakayama M; Kojima T; Namikawa K; Fujisawa T; Okano S; Hida E; Nakamura Y; Bando H; Yoshino T; Nonomura N
BMC Cancer; 2022 Dec; 22(1):1292. PubMed ID: 36494792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]